Tripterygium Glycosides Combined with Leflunomide for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Publisher: Hindawi Pub Country of Publication: United States NLM ID: 101215021 Publication Model: eCollection Cited Medium: Print ISSN: 1741-427X (Print) Linking ISSN: 1741427X NLM ISO Abbreviation: Evid Based Complement Alternat Med Subsets: PubMed not MEDLINE

Publication: 2011- : New York, NY : Hindawi Pub.
Original Publication: Oxford, UK : Oxford University Press, c2004-

Objective: To undertake an overview on the overall effects of Tripterygium glycosides (TG) combined with Leflunomide (LEF) for rheumatoid arthritis (RA).
Methods: We searched electronic databases from database establishment time to December 1, 2019. The clinical trial data of TG combined with LEF (trial group) and control group in the treatment of RA were collected. The Cochrane system was used to evaluate the quality of the literature. RevMan 5.3 software was used to conduct a meta-analysis of the eligible studies.
Results: A total of 12 randomized controlled trials (RCTs) involving 834 patients with RA were included in this study. The meta-analysis results showed that morning stiffness (mean difference (MD) = -0.29, 95% confidential interval (CI) (-0.45, -0.12), P =0.0005), tender joint count (MD = -1.51, 95% CI (-2.20, -0.83), P =0.0001), swollen joint count (MD = -1.24, 95% CI (-1.59, -0.88), P =0.0001), erythrocyte sedimentation rate (MD = -7.26, 95% CI (-9.92, -4.61), P =0.0001), C-reactive protein (MD = -4.04, 95% CI (-4.93, -3.14), P =0.0001), and rheumatoid factor (MD = -50.88, 95% CI (-72.30, -29.45), P  = 0.0001) in the trial groups were lower than those in the control groups. The total effective rate in the trial group was better than that in the control group (risk ratio (RR) = 1.20, 95% CI (1.13, 1.28), P =0.00001). However, there was no significant difference of adverse events (RR = 0.83, 95% CI (0.61, 1.13), P =0.23) while comparing the trial groups with the control groups.
Conclusion: Our results were found to be superior but limited evidence on the effectiveness of TG combined with LEF in the treatment of RA is available.
Competing Interests: The authors declare that there are no potential conflicts of interest.
(Copyright © 2020 Yi-Jing Yang et al.)

Rheumatology (Oxford). 2000 Jun;39 Suppl 1:48-56. (PMID: 11001380)
Acta Reumatol Port. 2006 Jul-Sep;31(3):215-24. (PMID: 17094333)
Ann Intern Med. 2015 Jun 2;162(11):777-84. (PMID: 26030634)
Am J Med. 2007 Nov;120(11):936-9. (PMID: 17976416)
Curr Opin Rheumatol. 2009 May;21(3):279-83. (PMID: 19318947)
Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
Immunopharmacology. 1998 May;39(2):117-26. (PMID: 9716258)
Biochem Biophys Res Commun. 2005 Feb 4;327(1):320-7. (PMID: 15629465)
Rheumatology (Oxford). 2013 Jan;52(1):53-61. (PMID: 23192911)
Drugs R D. 2003;4(1):1-18. (PMID: 12568630)
Eur J Pharmacol. 2004 Jun 21;494(1):1-9. (PMID: 15194445)
Arch Intern Med. 1999 Nov 22;159(21):2542-50. (PMID: 10573044)
Clin Rev Allergy Immunol. 2019 Jun;56(3):333-345. (PMID: 29372537)
Arthritis Rheum. 2004 Sep;50(9):2995-303. (PMID: 15457469)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 Mar;33(2):160-5. (PMID: 15067740)
BMC Pharmacol. 2004 Feb 17;4:2. (PMID: 15040811)

Date Created: 20200527 Latest Revision: 20220414

20240105

PMC7231184

10.1155/2020/1230320

32454846